Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 57,000 shares, a decrease of 18.6% from the October 31st total of 70,000 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily trading volume, of 36,200 shares, the short-interest ratio is currently 1.6 days.

Institutional Trading of Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. grew its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,500 shares of the company’s stock after acquiring an additional 24,000 shares during the period. Wedbush Securities Inc. owned about 0.78% of Marker Therapeutics worth $377,000 at the end of the most recent reporting period. 22.39% of the stock is owned by institutional investors and hedge funds.

Marker Therapeutics Stock Performance

Shares of NASDAQ MRKR opened at $3.50 on Friday. The company’s fifty day moving average is $3.35 and its two-hundred day moving average is $3.85. Marker Therapeutics has a one year low of $2.44 and a one year high of $6.16.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH raised their price target on Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a report on Monday, October 21st.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.